Semaglutide, administered once-weekly, has demonstrated significant efficacy in promoting substantial weight loss in adults who are overweight or obese. This research positions semaglutide as a powerful therapeutic option extending beyond its established role in type 2 diabetes management, marking a significant step forward in pharmacological approaches to obesity.